NZ514975A - Improvement of T cell mediated immunity - Google Patents

Improvement of T cell mediated immunity

Info

Publication number
NZ514975A
NZ514975A NZ514975A NZ51497500A NZ514975A NZ 514975 A NZ514975 A NZ 514975A NZ 514975 A NZ514975 A NZ 514975A NZ 51497500 A NZ51497500 A NZ 51497500A NZ 514975 A NZ514975 A NZ 514975A
Authority
NZ
New Zealand
Prior art keywords
improvement
cell mediated
mediated immunity
subject
cell population
Prior art date
Application number
NZ514975A
Inventor
Richard Lennox Boyd
Original Assignee
Univ Monash
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Monash filed Critical Univ Monash
Publication of NZ514975A publication Critical patent/NZ514975A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Abstract

A method of modifying the T-cell population makeup or increasing the number of T-cells in a subject having depressed or abnormal T-cell population of function, the method comprising disrupting sex steroid signaling to the thymus in the subject. Also disclosed are methods for enhancing an immune response to an antigen, treating an autoimmune disease and decreasing a host-vs-graft reaction in a transplantation recipient.
NZ514975A 1999-04-15 2000-04-17 Improvement of T cell mediated immunity NZ514975A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP9778A AUPP977899A0 (en) 1999-04-15 1999-04-15 Improvement of t cell mediated immunity
PCT/AU2000/000329 WO2000062657A2 (en) 1999-04-15 2000-04-17 Improvement of t cell mediated immunity

Publications (1)

Publication Number Publication Date
NZ514975A true NZ514975A (en) 2004-03-26

Family

ID=3813977

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ514975A NZ514975A (en) 1999-04-15 2000-04-17 Improvement of T cell mediated immunity

Country Status (11)

Country Link
EP (1) EP1191975A4 (en)
JP (1) JP2002542174A (en)
KR (1) KR20020007371A (en)
CN (1) CN100376288C (en)
AU (2) AUPP977899A0 (en)
BR (1) BR0009712A (en)
CA (1) CA2370296A1 (en)
HK (1) HK1046249A1 (en)
NZ (1) NZ514975A (en)
WO (1) WO2000062657A2 (en)
ZA (1) ZA200108451B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US20020071829A1 (en) * 1999-04-15 2002-06-13 Richard Boyd Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20020086000A1 (en) * 1999-04-15 2002-07-04 Richard Boyd Stimulation of thymus for vaccination development
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
IL155413A0 (en) * 2000-10-13 2003-11-23 Univ Monash Hematopoietic stem cell gene therapy
IL155412A0 (en) * 2000-10-13 2003-11-23 Univ Monash Diagnostic indicator of thymic function
AU2002216323C1 (en) * 2000-10-13 2008-05-29 Norwood Immunology Ltd Disease prevention by reactivation of the thymus
AU2002216320C1 (en) * 2000-10-13 2008-04-03 Norwood Immunology Ltd Hematopoietic stem cell gene therapy
AU2002225245C1 (en) * 2000-10-13 2008-07-17 Norwood Immunology Ltd Improvement of graft acceptance through manipulation of thymic regeneration
WO2002030259A2 (en) * 2000-10-13 2002-04-18 Monash University Disease prevention by reactivation of the thymus
CN1479638A (en) * 2000-10-13 2004-03-03 Ī��ʲ��ѧ Improvement of graft acceptance through manipulation of thymic regeneration
AU2001295270B2 (en) * 2000-10-13 2007-08-09 Norwood Immunology Ltd Treatment of T cell disorders
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
EP1620126A4 (en) * 2003-04-18 2007-07-04 Norwood Immunology Ltd Disease prevention and vaccination prior to thymic reactivations
AU2008297411A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
BR112013033988B1 (en) * 2011-07-01 2021-10-19 Beckman Coulter, Inc. METHODS FOR IDENTIFICATION AND ISOLATION OF ONE OR MORE POPULATIONS OF IMMUNOSUPPRESSIVE REGULATORY T CELLS
CN103235135B (en) * 2013-04-26 2015-02-04 史其新 Detection method of characteristic cell mass for representing inhibitory activity of peripheral regulatory T cell, and application thereof
CN110691600B (en) * 2016-11-11 2024-04-16 美商生命科学有限公司 Method for realizing cell immunity and humoral immunity by using human mesenchymal stem cells
US11819520B2 (en) 2018-02-23 2023-11-21 Duke University Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants
EP3755346A4 (en) * 2018-02-23 2022-03-09 Duke University & Medical Center Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001176A1 (en) * 1986-08-18 1988-02-25 Bunge (Australia) Pty. Ltd. Regulating animal reproduction
AU634379B2 (en) * 1991-04-29 1993-02-18 Csl Limited Recombinant immunocastration vaccine

Also Published As

Publication number Publication date
AU779067B2 (en) 2005-01-06
ZA200108451B (en) 2003-01-15
CN1364093A (en) 2002-08-14
AU3797700A (en) 2000-11-02
KR20020007371A (en) 2002-01-26
CA2370296A1 (en) 2000-10-26
EP1191975A4 (en) 2005-05-25
HK1046249A1 (en) 2003-01-03
JP2002542174A (en) 2002-12-10
CN100376288C (en) 2008-03-26
WO2000062657A2 (en) 2000-10-26
BR0009712A (en) 2002-04-30
WO2000062657A3 (en) 2001-01-11
EP1191975A2 (en) 2002-04-03
AUPP977899A0 (en) 1999-05-13

Similar Documents

Publication Publication Date Title
NZ514975A (en) Improvement of T cell mediated immunity
ZA986084B (en) CTL epitopes from EBV
SG165132A1 (en) Substantially pure histidine-linked protein polymer conjugates
IL112390A0 (en) A cell which expresses chimeric receptors, DNA and vectors encoding said receptors and pharmaceutical compositions containing the same
NZ302513A (en) Chimeric receptors for redirecting cellular immunity
EP0851651A3 (en) Voice mail embedded executable responses
IL147803A0 (en) 28-epirapalogs
NZ333607A (en) Method of stimulating the immune system by transfecting dendritic cells
AU2002364935A1 (en) Enhancement of immune responses by 4-1bb-binding agents
WO2008033403A3 (en) Agents and methods to elicit anti-tumor immune response
HK1037925A1 (en) Herpes virus vectors for dendritic cells
TR199801395A2 (en) Genetically modified cells and their uses.
AU2002359666A1 (en) Method for the generation of antigen-specific lymphocytes
GB2355983B (en) Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class 1 molecule and an attaching means
HK1048498A1 (en) Method of proliferating natural killer cells
HUP0200484A2 (en) Antibody and chemokine constructs that are directed to ccr5, and their use for treating autoimmune diseases
EP0906335A4 (en) Ebv ctl epitopes
EP0898969A3 (en) Neospora vaccine
AU5211200A (en) Method for diminishing specific immune reactions
AU8349301A (en) Dna vaccines encoding hiv accessory proteins
AU2000273396A1 (en) Hla binding peptides and their uses
GB2379446A (en) Cells,culture methods and their uses
AU1062501A (en) Dendritic cells activated in the presence of glucocorticoid hormones are capableof suppressing antigen-specific t cell responses
GB9726897D0 (en) Process
WO2000069898A8 (en) Molecular interactions in allergy cells

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
ASS Change of ownership

Owner name: NORWOOD IMMUNOLOGY LTD, AU

Free format text: OLD OWNER(S): NORWOOD IMMUNOLOGY LTD; MONASH UNIVERSITY

RENW Renewal (renewal fees accepted)